1. Home
  2. GF vs MDXH Comparison

GF vs MDXH Comparison

Compare GF & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GF

New Germany Fund Inc. (The)

HOLD

Current Price

$11.43

Market Cap

184.9M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.47

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GF
MDXH
Founded
1990
2003
Country
Germany
Belgium
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
184.9M
167.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GF
MDXH
Price
$11.43
$3.47
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
28.1K
123.4K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
0.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$7.38
$1.35
52 Week High
$9.41
$5.33

Technical Indicators

Market Signals
Indicator
GF
MDXH
Relative Strength Index (RSI) 62.87 47.75
Support Level $11.18 $3.11
Resistance Level $11.51 $3.58
Average True Range (ATR) 0.15 0.17
MACD 0.04 0.04
Stochastic Oscillator 82.96 63.25

Price Performance

Historical Comparison
GF
MDXH

About GF New Germany Fund Inc. (The)

NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: